Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

In silico Mutagenesis and Modeling of Decoy Peptides Targeting CIB1 to Obscure its Role in Triple-negative Breast Cancer Progression

Author(s): Muhammad Shahab, Chaoqun Liang, Xiuyuan Duan, Guojun Zheng* and Abdul Wadood*

Volume 29, Issue 8, 2023

Published on: 29 March, 2023

Page: [630 - 638] Pages: 9

DOI: 10.2174/1381612829666230327162852

Price: $65

Abstract

Background: Cancer is recognized globally as the second-most dominating and leading cause of morbidities. Breast cancer is the most often diagnosed disease in women and one of the leading causes of cancer mortality. In women, 287,850, and in males, 2710 cases were reported in 2022. Approximately 10-20% of all new cases of breast cancer diagnosed in the United States in 2017 were triple-negative breast cancers (TNBCs), which lack the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).

Objective: This study aims to adopt different strategies for targeting calcium integrin-binding protein 1 by computer- aided drug design methods. Our results showed that the top four selected peptides interact with CIB1 more strongly than the reference peptide and restore normal cell function by engaging CIB1. Our binding affinity analyses explore an innovative approach to planning a new peptide to inhibit triple-negative breast cancer.

Methods: Molecular dynamic simulation of the CIB1-UNC10245092 interaction highlights the potential peptide inhibitors through in-silico mutagenesis and designs novel peptide inhibitors from the reference peptide (UNC10245092) through residue scan methodology.

Results: The top four designed peptides (based on binding free energy) were subjected to molecular dynamics simulations using AMBER to evaluate stability.

Conclusion: Our results indicate that among the top five selected peptides, the mutant 2nd mutants have more potential to inhibit CIB1 than the reference peptide (UNC10245092) and have the potency to prevent or restore the tumor suppressor function of UNC10245092.

Keywords: CIB1 protein, breast cancer, TNBCs, HER2, per-mutations, MD simulation.

« Previous
[1]
Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010; 7(5): e1000279.
[http://dx.doi.org/10.1371/journal.pmed.1000279] [PMID: 20520800]
[2]
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121(7): 2750-67.
[http://dx.doi.org/10.1172/JCI45014] [PMID: 21633166]
[3]
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15): 4429-34.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-3045] [PMID: 17671126]
[4]
Lee A, Djamgoz MBA. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev 2018; 62: 110-22.
[http://dx.doi.org/10.1016/j.ctrv.2017.11.003] [PMID: 29202431]
[5]
Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69(2): 565-72.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-3389] [PMID: 19147570]
[6]
Gordon V, Banerji S. Molecular pathways: PI3K pathway targets in triple-negative breast cancers. Clin Cancer Res 2013; 19(14): 3738-44.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0274] [PMID: 23748695]
[7]
Naik UP, Patel PM, Parise LV. Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem 1997; 272(8): 4651-4.
[http://dx.doi.org/10.1074/jbc.272.8.4651] [PMID: 9030514]
[8]
Yuan W, Leisner TM, McFadden AW, et al. CIB1 is an endogenous inhibitor of agonist-induced integrin αIIbβ3 activation. J Cell Biol 2006; 172(2): 169-75.
[http://dx.doi.org/10.1083/jcb.200505131] [PMID: 16418530]
[9]
Rusnak F, Mertz P. Calcineurin: Form and function. Physiol Rev 2000; 80(4): 1483-521.
[http://dx.doi.org/10.1152/physrev.2000.80.4.1483] [PMID: 11015619]
[10]
Gentry HR, Singer AU, Betts L, et al. Structural and biochemical characterization of CIB1 delineates a new family of EF-hand-containing proteins. J Biol Chem 2005; 280(9): 8407-15.
[http://dx.doi.org/10.1074/jbc.M411515200] [PMID: 15574431]
[11]
Tahara E Jr, Tahara H, Kanno M, et al. G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother 2005; 54(8): 729-40.
[http://dx.doi.org/10.1007/s00262-004-0645-2] [PMID: 15685448]
[12]
Yuan W, Leisner TM, McFadden AW, et al. CIB1 is essential for mouse spermatogenesis. Mol Cell Biol 2006; 26(22): 8507-14.
[http://dx.doi.org/10.1128/MCB.01488-06] [PMID: 16982698]
[13]
Naik MU, Pham NT, Beebe K, Dai W, Naik UP. Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells. Int J Cancer 2011; 128(3): 587-96.
[http://dx.doi.org/10.1002/ijc.25388] [PMID: 20473878]
[14]
Nagayoshi Y, Nakamura M, Matsuoka K, et al. Profiling of autoantibodies in sera of pancreatic cancer patients. Ann Surg Oncol 2014; 21(S3): 459-65.
[http://dx.doi.org/10.1245/s10434-014-3574-0] [PMID: 24585405]
[15]
Heineke J, Auger-Messier M, Correll RN, et al. CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med 2010; 16(8): 872-9.
[http://dx.doi.org/10.1038/nm.2181] [PMID: 20639889]
[16]
Blazejczyk M, Wojda U, Sobczak A, et al. Ca2+-independent binding and cellular expression profiles question a significant role of calmyrin in transduction of Ca2+-signals to Alzheimer’s disease-related presenilin 2 in forebrain. Biochim Biophys Acta Mol Basis Dis 2006; 1762(1): 66-72.
[http://dx.doi.org/10.1016/j.bbadis.2005.09.006] [PMID: 16257512]
[17]
Shahab M, Wadood A, Zheng G. Strategies for targeting CIB1: A challenging drug target. Curr Pharm Des 2022; 28(28): 2348-8.
[18]
Sussman JL, Lin D, Jiang J, et al. Protein Data Bank (PDB): Database of three-dimensional structural information of biological macromolecules. Acta Crystallogr D Biol Crystallogr 1998; 54(6): 1078-84.
[http://dx.doi.org/10.1107/S0907444998009378] [PMID: 10089483]
[19]
Molecular operating environment (MOE). Chemical Computing Group Inc. 2016.
[20]
Kortemme T, Kim DE, Baker D. Computational alanine scanning of protein-protein interfaces. Sci STKE 2004; 2004(219): pl2-2.
[http://dx.doi.org/10.1126/stke.2192004pl2] [PMID: 14872095]
[21]
Massova I, Kollman PA. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discov Des 2000; 18(1): 113-35.
[http://dx.doi.org/10.1023/A:1008763014207]
[22]
Bro R, Smilde AK. Principal component analysis. Anal Methods 2014; 6(9): 2812-31.
[http://dx.doi.org/10.1039/C3AY41907J]
[23]
Amadei A, Linssen ABM, Berendsen HJC. Essential dynamics of proteins. Proteins 1993; 17(4): 412-25.
[http://dx.doi.org/10.1002/prot.340170408] [PMID: 8108382]
[24]
Ying-Chang Liang , Chin FPS. Downlink channel covariance matrix (DCCM) estimation and its applications in wireless DS-CDMA systems. IEEE J Sel Areas Comm 2001; 19(2): 222-32.
[http://dx.doi.org/10.1109/49.914500]

Rights & Permissions Print Cite
Article Metrics
15
2
© 2024 Bentham Science Publishers | Privacy Policy